NCT01743118 - Antipsoriatic Effect of a Topical Formulation for the Treatment of Psoriasis Vulgaris | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions

Psoriasis Vulgaris

Interventions

DRUG

SPS4251 Ointment

Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)

DRUG

Placebo

Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)

DRUG

Daivonex® ointment

Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments).

Trial Locations (2)

Unknown

Bioskin, Berlin

Bioskin, Hamburg